• Victory Square invests in innovative, game-changing entrepreneurs
• Provides entrepreneurs access to education programs, global mentorship networks, distribution partners, and other resources
• Company has secured multiple early partnerships and investments in the blockchain space

Victory Square Technologies Inc. (CSE: VST) (OTC: VSQTF) (FRANKFURT: 6F6) (WKN: A2AKL8) is a venture builder that creates, funds and empowers entrepreneurs working in the fields of blockchain technology, virtual reality, artificial intelligence, personalized health, gaming and film. As a technology incubator, Victory Square invests in game-changing entrepreneurs who are provided access to education programs, global mentorship networks, distribution partners, creative workspaces, resources, and other forms of operational support to help them scale internationally.

Victory Square has made multiple early partnerships and investments in the blockchain space. Approximately three years ago the company incubated and invested in BTL Group, which is now a $150 million dollar TSX-listed company offering blockchain solutions across multiple industries with particular focus on the finance, energy and gaming sectors. BTL’s showcase product – Interbit – is a blockchain platform that facilitates the rapid development of business applications that dramatically improve efficiency. Some of the world’s largest institutions are using Interbit to explore new opportunities on private blockchains.

A new social sports betting platform to be developed by Victory Square’s wholly owned subsidiary, FansUnite Media Inc. As a social sports data platform, FansUnite relies on robust data to allow members of its community to engage with like-minded individuals by collaborating, discussing, and predicting the winners of sporting events with a free virtual currency. The integration of blockchain technology into FansUnite’s social sports data platform could also lead to blockchain initiatives developed by other divisions and subsidiaries of Victory Square.

Integral to the FansUnite platform is the introduction of FAN Tokens, an in-game currency purchased with the cryptocurrency Ethereum that token holders can use to place wagers. FansUnite members will be able to earn FAN Tokens through participation in any number of networking effects identified in the company’s Bounty program.

“Blockchain technology and the inherent security it provides will enable us to push every envelope we can to build the most dynamic and responsive social sports betting platform,” said Darius Eghdami, Co-Founder and Chief Executive Officer of FansUnite. “The opportunity to secure data through Blockchain certainly appeals to the accountant in me and we are confident it will become the gold standard among sports betting sites around the world.”

Company subsidiary Victory Square Health Inc., which serves as the venture arm dedicated to companies focused on the development of solutions in personalized health technologies, has also invested in Personalized Biomarkers Inc. (PBI). PBI develops test kits that reliably predict the expected response to a number of therapies prior to prescription, with an initial focus on diabetes. Within this field, five potential biomarkers have been identified, allowing PBI to enter a $4 billion market opportunity.

“We are excited for the opportunity to partner with Personalized Biomarkers as they have correctly identified a massive market opportunity, and have formed an exceptional team of industry leaders,” said Shafin Diamond Tejani, Chief Executive Officer of Victory Square. “This is another investment that is fully aligned with our newly created subsidiary, and one we expect to significantly impact the landscape of personalized medicine.”

A partnership with Insight Diagnostics Inc., also through Victory Square Health, will focus on the development of a personalized diagnostic solution for the improved management and prevention of Type II diabetes.

The company’s investment in V2 Games, a development and publishing studio of high-quality mobile games, is another example of incubating great ideas. V2 Games is well known for its successful launch of PAC-MAN Bounce and Beast Brawlers, two of the company’s releases that are capturing the gaming world by the millions of downloads.

In a move designed to strengthen its presence in film and entertainment, Victory Square has acquired a 40 percent equity stake in United Film Fund II, LLC, which is producing three major motion pictures in 2017 and 2018 including “What They Had,” starring two-time Academy Award winner Hilary Swank.

“This kind of investment in entertainment and film represents a major plank for our Company going forward and we consider ourselves fortunate to have the opportunity to acquire this 40% stake in the Film Fund,” said Tejani, who has launched more than 40 startups in 21 countries that employ hundreds of people and generate more than $100 million in annual revenues. “We believe it’s another strong initiative in film production for us and our stakeholders,” he added.

Victory Square has strategically positioned itself in the legal cannabis industry through an investment in Tantalus Labs, a Canadian-based cannabis cultivation company. Tantalus Labs optimizes plant health and sustainable cultivation by using a unique, environmentally controlled greenhouse engineered specifically for growing cannabis. Called a “SunLab,” the greenhouse takes 90 percent less electricity, uses filtered rainwater, and cools the growing environment to prevent stagnant moisture, recycling the air every 7 minutes to achieve maximum airflow.

Victory Square and its leadership team have seamlessly transitioned from its former identity as Fantasy 6 Sports Inc, a company focused solely on fantasy sports, mobile gaming and immersive sports, to a strategic technology company that creates, funds and successfully executes leading-edge ideas. A long-time technology entrepreneur and advocate of the industry, Tejani received the Person-of-the-Year Award at the 2017 Technology Impact Awards in British Columbia, a hallmark award category that recognizes betterment of the tech industry through leadership and philanthropic or enterprise skills and talents. Tejani has pledged to match up to $1 million in donated funds to be shared by a number of Canadian endeavors aimed at education and child-safe projects.

“These are exciting and important steps in the evolution and growth of our Company, and which properly and fully align with our strategic plan focusing on our core competencies in Blockchain Technology, Artificial Intelligence, Gaming, Personalized Health, Film and Virtual, Augmented and Mixed Reality,” said Tejani. “We’re spurred on by the success we have had in building on our original forays into fantasy sports, mobile gaming and immersive sports. In addition, we are energized by our most recent initiatives in sports, personalized health and entertainment and the confidence being shown by our shareholders in the dynamic direction of the Company.”

Victory Square Technologies and its management team believe innovation, incubation of excellent ideas and social responsibility are at the core of its growing success.

For more information, visit the company’s website at www.VictorySquare.com

Let us hear your thoughts: Victory Square Technologies Inc. Message Board

• LTTGF disrupts the market and lottery ticket purchase methods, making it easier than ever to get in on the game
• Customers can quickly and conveniently pool tickets to increase odds
• The innovative company employs a strategic business model to expand to 22 additional states and allow enhanced digital payment options

While the chances of hitting the jackpot in any major American lottery game are one in millions, the old adage that “you have to be in it to win it” rings true no matter the odds. LottoGopher Holdings Inc. (OTCQB: LTTGF) (CSE: LOTO) (FSE: 2LG) makes it easier than ever to get in on the game. The Los Angeles based company disrupts the market and the old way of purchasing tickets, and redefines convenience from even the ease of a quick stop at a “convenience” store to bringing purchase options to its customers to order lottery tickets online. LTTGF provides a quick, innovative and convenient way for California residents to purchase tickets online for Powerball, Mega Millions and/or California’s own SuperLotto Plus.

And, while a player’s odds increase with the simple purchase of a ticket (i.e., from zero to one in millions for the jackpot or zero to one in 23 to 25 for winning any prize, depending on the game), LTTGF customers can quickly and conveniently pool tickets to further increase odds of winning.

LTTGF customers buy tickets online at face value, without additional markups, based on membership-level payment options for use of the service. The messenger service purchases tickets at a physical location, as well as provides membership access to its online system and tracking functionality. First single-ticket orders are allowed with free membership and, thereafter, membership options include a daily, monthly or yearly subscription for use of the service.

Subscriber perks include options to:

• Monitor exclusive membership information, such as strategies, alerts and current lottery news.
• Create groups and take office or other friends and family pools online, while running and tracking with the online service.
• Browse and join public lottery pools, which range from two to 100 members per group, and utilize the service to find groups that are winning often, groups that seem overdue for a big prize, play in multiple groups, play in local or similar-interest groups, or find groups employing appealing methods of number selection, etc.

LTTGF service is currently available to California residents only, with a strategic business model and plans to expand to 22 additional states by year-end 2018. The company has joined forces with Lottoland, the online lottery world leader, and it is working to enhance cashless options to allow encrypted payment with digital cryptocurrencies.

For more information, visit the company’s website at www.LottoGopher.com

Let us hear your thoughts: LottoGopher Holdings Inc. Message Board

• Veritas Pharma is unlocking the science underlying medical cannabis
• Clinically profiling select cannabis strains – pharmacologically identifying strains for specific disease conditions
• Entering human clinical studies with valuable IP’s in place

There is growing support for medicinal cannabis. Repeated peer-reviewed studies have demonstrated positive patient responses in a variety of maladies. However, to date, the response has been largely anecdotal, and, unlike rigorous pharmacology, the precise mechanisms and chemical profiles of cannabinoids remain unknown.  Through exacting scientific protocols, Veritas Pharma Inc. (CSE: VRT) (OTC: VRTHF) (FRT: 2VP) is about to radically change the understanding and applications of this millennia-old medicine.

Led by experienced management and bolstered with veteran academic pharmacologists, anesthetists and chemists, Veritas Pharma is rapidly unlocking the science underlying medical cannabis. The company chemically profiles different marijuana cultivars (specific plant varieties produced in cultivation by selective breeding). The cultivars are then pharmacologically profiled to identify disease-specific strains, and once these stringent protocols are achieved, Veritas performs clinical trials to establish the clinical utility and efficacy of each cultivar.

After exhaustive chemical and animal assays delivered favorable results, Veritas recently announced its research subsidiary, Cannevert Therapeutics Ltd., has signed a letter of intent to initiate the human study of CTL-X, the company’s lead cannabis strain targeting pain (http://dtn.fm/i92nV). The study will be undertaken at Fundación de Investigación, a highly respected clinical research center with state-of-the-art facilities and in-house bioanalytical laboratory located in San Juan, Puerto Rico. Veritas’s CEO Lui Franciosi stated in part, “It’s important to us to move quickly into this next phase of providing clinical proof of cannabis’ effectiveness….We aim to provide physicians and patients with scientifically tested and clinically proven cannabis therapies targeting pain.  In the next year, Veritas’s goal is to have a branded analgesic strain in which its dose and method of administration are standardized to actively compete with over-the-counter analgesics as well as potentially reducing or eliminating opioid use in the acute and chronic pain markets.”

Delivering scientifically tested and clinically proven standardized cannabis therapies is a potential game changer throughout the entire nascent medical cannabis industry. In addition to developing clinically proven effective cannabis strains (cultivars) specific to pain, Veritas is targeting pain, nausea, epilepsy and PTSD. During development of these therapies, the company institutes broad patent protections for its potential blockbuster intellectual properties. Targeting multi-billion dollar global markets, the company’s unique value proposition uses a low-cost research and development model to drive speed-to-market. Veritas intends to license or sell its IP’s to cancer clinics, the insurance industry and pharmaceutical companies.

Anecdotally embraced, the rush into marijuana as medicine has been hamstrung by lack of pharmacologically profiled, scientifically tested, clinically proven therapies. Real medicine requires real science. Veritas Pharma is poised to deliver the requisite real science and indelibly transform medical cannabis therapeutics.

Let us hear your thoughts: Veritas Pharma Inc. Message Board

For more information, visit the company’s website at www.VeritasPharmaInc.com

• Tapinator games garner hundreds of thousands of daily downloads, millions of players, and coveted “New Games We Love” distinctions
• Strategic releases include highly anticipated puzzle game “ColorFill” in advance of holiday shopping season, as part of aggressive Full-Featured release strategy
• Business strategy reflects staying power and ability to tap into the healthy and growing revenues of the global gaming industry

Tapinator, Inc. (OTCQB: TAPM), a leading developer of mobile games on the iOS, Google Play, and Amazon platforms, is tapping into the growing mobile gaming market with staying power based on a strategic release schedule, strong business model, and unique revenue-generating approach, that produces a consistent and attractive return on investment.

The company, recently featured in an editorial titled, “Highly Anticipated Game Releases” (http://dtn.fm/1qeEt), has built a broad portfolio of over 300 mobile games that have been downloaded by more than 450 million players worldwide. Hailed as “One to Watch” (http://dtn.fm/x2UUj) within the mobile gaming market, TAPM has garnered considerable market attention recently with its hundreds of thousands of daily player downloads, and hit releases of “Big Sport Fishing 2017” and “Dice Mage 2” both of which were distinguished as “New Games We Love” on the Apple iOS platform (http://dtn.fm/7B5Qn).

Among highly-anticipated new releases is the Company’s puzzle game, “ColorFill” that is scheduled for worldwide release on December 7, 2017. Available just in time for the holiday shopping season, this new revolutionary puzzle game blends features and elements similar to those found in popular games such as “Sudoku” and “Minesweeper” in order to attract a large loyal audience and create a new classic.

TAPM’s offerings include best-in-class titles intended to entertain consumers over a long period, which the Company refers to as “Full-Featured Games.” These products include TAPM’s popular titles, such as “ROCKY^™” and “Solitaire Dash.” The Full-Featured line collectively hit a cord with the gaming community, reflecting a 255 percent growth in bookings through the third quarter of 2017. Based on this momentum, Tapinator just announced a Full-Featured release strategy (http://dtn.fm/vW5Z7) that is two-fold: (i) optimize existing hit games in terms of engagement and monetization and (ii) release new games with great home run and/or long-term/evergreen potential.

In addition to its Full-Featured titles, the Company offers a wide and strong selection of simple, simulation-style mobile games, which it refers to as Rapid-Launch Games. These are hard-hitting games with low development costs that are very popular in the mobile gaming community, often based on current and popular trends.

Across Tapinator’s large catalog of games, virtual goods can be purchased via in-app purchases to enhance the gameplay experience. By blending consumer app store transactions with the Company’s sale of strategically-placed branded advertisements, TAPM has managed to generate consistent and attractive investment returns.

TAPM’s business model and aggressive release strategy reflect its staying power and ability to tap into the strong growth of global mobile gaming, which Statistics portal Statista.com forecasts will have grown to $188.9 billion by 2020, up from $69.7 billion in 2015. As reflected in a recent Morningstar article titled, “Should You Stuff Your Stocking With Video Game Stocks?” (http://dtn.fm/PV8dG), TAPM’s strategies for enhancing the engagement of current users and increasing revenue from existing games is right in line with industry leaders and presents a ripe opportunity to increase revenue and grow margins. Explained by George Cipolloni, a portfolio manager at Chartwell Investment Partners and manager of Berwyn Income, this is a boon to margins, “If you’re buying extra ammo or weapons, that’s really additive to the bottom line,” he says. “It’s pure margin for these companies, and we have seen margins and free cash exploding as a result.”

For more information, visit the company’s website at www.Tapinator.com

Let us hear your thoughts: Tapinator, Inc. Message Board

• Targeting unmet medical needs with proprietary topical formulations
• License-based business model translates to worldwide opportunities
• Patented Invisicare™ technology offers enhanced drug delivery system
• Global skincare market projected to reach $135 billion by 2021

Research and development company Skinvisible Pharmaceuticals, Inc. (OTCQB: SKVI), continues to add significant value to its core business model with several key movements involving a proposed merger, new licensing agreements and formation of a specialized subsidiary.

The Company’s November 27 announcement that it has entered into a non-binding term sheet regarding a proposed merger with Quoin Pharmaceuticals Ltd., pending customary closing conditions, melds industry veterans committed to developing products which address major societal issues with Skinvisible’s team of R&D scientists. Quoin’s two lead products are targeting crises such as the opioid epidemic and the military veteran suicide rate that result in the death of almost 120 people in the United States every day (http://dtn.fm/4eOib).

Skinvisible has developed over 40 product formulations using Invisicare both in the medical and skincare markets, in addition to being granted 14 patents. The company is focused on licensing its formulations and Invisicare to other companies in the pharmaceutical and cosmeceutical industries. The Company’s business model emphasizes four revenue streams that include fees for new product development, license fees, sales of branded products, and on-going royalty fees based on a licensee’s sales.

There’s plenty of room for Skinvisible’s proprietary technology within the skincare, dermatology and over-the-counter cosmeceutical markets, as evidenced by numerous reports from MarketResearch.com which state the global skincare market alone is projected to reach $135 billion by 2021 (http://dtn.fm/7wIdB).

In September, Skinvisible announced it had signed a licensing agreement with Canopy Growth Corporation, the world’s largest cannabis company.  This was followed in November when Skinvisible reported it had formed a new subsidiary, Ovation Science Inc., for the purpose of better serving the needs of licensees, as well as to focus on specific product development within the cannabis market. In fact, Ovation Science has already reached a licensing agreement with Cannabiniers, a subsidiary of Lighthouse Strategies, LLC, to distribute Skinvisible’s patented cannabis products to select markets in the United States where medical cannabis products have been legalized (http://dtn.fm/V2Exx). Invisicare’s game-changing technology enhances topical and transdermal drug delivery, enabling improved release and penetration of the product.

Another milestone was reached in June of this year when the Company first sold its hand sanitizer DermSafe product in China. Clinical studies show that frequent hand washing and sanitization is an effective way to help prevent the spread of flu viruses, including some of the more virulent forms now being seen around the world (http://dtn.fm/sJy9O). Interestingly, DermSafe was used by the Canadian Olympic team during the games in Rio, addressing concerns stemming from poor water quality through the use of the hand sanitizer. The Canadian Olympic team will also be protected by DermSafe in February 2018 at the Winter Olympic Games in South Korea.

For more information, visit the company’s website at www.Skinvisible.com

Let us hear your thoughts: Skinvisible, Inc. Message Board

• Report predicts 20 percent of back office payment shifting to BPaaS by 2021
• Company has eight new health care services contracts rolling out in early 2018
• IOSOFT applications are compliant with integration requirements for firms such as Blue Cross, Aetna and CIGNA

Health care industries are experiencing a growing push to streamline services and increase their transparency with patients (http://dtn.fm/O9wnd) amid continued volatility in health care and insurance industry politics (http://dtn.fm/2g4cK). RJD Green, Inc. (OTC: RJDG) is among a variety of enterprises providing smart-business solutions to help meet the digital needs of tomorrow’s industries.

RJD Green is a holding company focused on acquiring and managing businesses with proven revenue track records. It has subsidiaries in environmental services and specialty construction, as well as the health care services industry.

RJDG’s IOSOFT Inc. is providing discrete payment applications through software and services being incorporated into health care provider networks, enabling hospitals, individual providers and health care payers to work together more seamlessly. IOSOFT software applications are being integrated by third party administrators and other medical services providers nationally.

“From ongoing negotiations that are occurring now, we expect to see more accelerated monthly contracts procured in the first calendar quarter of 2018,” IoSoft President Vincent Valentine stated in a September news release.

The company has eight health care services contracts that it expects to launch during the first quarter of 2018. It is anticipating revenue of $9.6 million over the course of the year.

A November IDC Health Insights report titled ‘Worldwide Health Industry 2018 Predictions’ forecasts that, by 2021, 20 percent of commercial payer back office operations will have been shifted to cloud outsourcing contracts (BPaaS) in order to meet overwhelming data management requirements (http://dtn.fm/exX3x). The report also predicts that digital tracking of assets and inventory through Internet of Things network-enabled hospital systems will have doubled worldwide by 2020 as part of the trend.

In addition to RJD Green’s positioning for health care industry advances, the company owns its Earthlinc Environmental Services Division, which furthers technologies and services in green industries, as well as its Silex Holdings Division, a manufacturing company that fills a market niche between home improvement retailers and local contractors with specialties in granite counter tops, cabinets and related products. Silex has forecast revenue and profit growth of 50 percent in 2018.

For more information, visit the company’s website at www.RJDGreen.com

Let us hear your thoughts: RJD Green Inc. Message Board

• Alibaba and Amazon dominate global e-commerce
• ChineseInvestors.com just successfully launched first hemp-infused skin care products in China
• Company aims to dominate market

When considering e-commerce, Amazon is usually the first name that pops up. However, Alibaba is, by many metrics, both China’s and the world’s largest online e-commerce company. Alibaba commands about 50% market share of business-to-consumer e-commerce in China, while Amazon is the e-commerce elephant in the United States, garnering about 44% of e-commerce sales. To achieve maximum market penetration and global exposure, ChineseInvestors.com, Inc. (OTCQB: CIIX) just successfully launched its OptHemp Product Line on both Amazon and Alibaba.

Initially launched as a specialized investment services company providing real-time commentary, analysis and educational related services in the Chinese language, ChineseInvestors.com’s long-term quest for value-add opportunities led it to stake out a position in the explosive new medical CBD market. With nearly two decades of brand recognition, a 100,000+ user base and a target market of nearly two billion Chinese-speaking people, ChineseInvestors.com launched into the CBD market in 2016. Simultaneously, the company continued to expand its core investor education business, adding a Chinese speakers-targeted daily video telecast on cryptocurrencies, and recently announce a 186 percent jump in sales for 1Q2018 in its investor relations division.

In addition to nurturing its legacy business to record growth, ChineseInvestors.com has established a significant footprint in the global CBD market in only one year. The company’s latest foray into the CBD market may be its boldest and, potentially, most profitable endeavor to date, as it aims to dominate the entire hemp-infused skin care products market throughout China. The company retails its hemp oil-based cannabidiol (CBD) products on Alibaba and Amazon under the “OptHemp” brand through its wholly-owned subsidiaries, CBD Biotechnology Co. Ltd. and ChineseHempOil.com, Inc. As indication of consumer acceptance, the company’s “CBD Magic Hemp Series” generated 40,000 views and registered over 91 units purchased just minutes after launch. Commenting on the overwhelming response to its product launch, ChineseInvestors.com CEO Warren Wang stated that it “solidifies our belief that Chinese consumers recognize that the anti-inflammatory agents and anti-oxidants contained in hemp-extract can have positive effects on the skin.”

In business for nearly two decades and with a track record of stellar revenue growth and strategic diversification, the company is primed to capitalize on its position as the first to market in China with hemp-infused skin care products through its partnerships with global e-commerce behemoths. These factors certainly suggest strong upside potential for ChineseInvestors.com.

For more information, visit the company’s website at www.ChineseInvestors.com

Let us hear your thoughts: ChineseInvestors.com, Inc. Message Board

• Proven patented polymer drug delivery technology
• Global topical drug delivery market set for CAGR of 9.2% over next 7 years
• Strategy to derive revenues from royalties and other licensing fees

Skinvisible, Inc. (OTCQB: SKVI) is set for a business renaissance in the coming years. The Nevada-based Company, which develops topical, transdermal and mucosal polymer-based drug delivery systems and formulations that incorporates its patent-pending technology for combining hydrophilic and hydrophobic polymer, is a player in an industry poised to double in size over the next seven years. A new market research report estimates the global topical drug delivery market will grow at a CAGR of 9.2% from USD 101.7 billion in 2016 to reach USD 205.1 billion by 2024. This is good news for Skinvisible, which derives part of its revenues from royalties and other product licensing fees. The Company is already having success in this area. It has announced a number of licensing agreements. As the global topical market continues its robust growth, Skinvisible’s licensing business appears more than skin deep.

The glowing Global Topical Drug Delivery Market 2017-2024 report by Data Bridge Market Research details some of the factors expected to drive market growth (http://dtn.fm/5Vl4i). In some instances, topical technologies have exhibited superior therapeutic outcomes, by improving the delivery of active ingredients to a targeted site, in responding to inter-and intra-patient differences without fluctuations in drug levels, and in higher levels of patient compliance.

Although the Data Bridge survey covered all skin-administered delivery systems, the term “topical” is also applied more narrowly to a medication intended to have an effect at the site of application. Such topical applications typically do not result in significant drug concentrations in the blood and other tissue and cause fewer adverse reactions. They are contrasted with transdermal medications, which are absorbed through the skin or mucosal membranes, and are intended to have an effect in areas of the body away from the site of application. Transdermal administration is an excellent method to use when a patient is unable to swallow or for medications that are significantly metabolized by the liver, and is frequently utilized for anti-nausea drugs, hormone replacement therapy, and generalized pain. In addition to these technical factors, an increasing aging population and the growing prevalence of skin related ailments will undoubtedly contribute to topical market growth. With such rapid market expansion in the offing, drug marketers will have to rely on R&D companies like Skinvisible and their novel delivery technologies.

The backbone of Skinvisible’s licensing strategy is its Invisicare® technology, which is now truly time-tested after 15 years’ utilization in developing a portfolio of over 40 prescription, over-the-counter (OTC) and cosmeceutical products. Invisicare is a high performance polymer technology that improves how products are delivered to the skin. It improves the release of active ingredients, increases the binding of the product to the skin, improves the stabilization of ingredients and can improve efficacy, safety and consumer satisfaction. Skinvisible’s Invisicare technology enjoys comprehensive patent protection. A prescription dermatology product can generate $100 million or more a year.

For more information, visit the company’s website at www.Skinvisible.com

Let us hear your thoughts: Skinvisible, Inc. Message Board

• Major interest generated in Lexaria’s technology at MJBizCon
• Patented technology masks bitter taste of edibles, increases bio-absorption and reduces time to effect
• Lexaria’s proprietary tech enables lowest manufacturing cost per serving and best consumer experience

This year’s three-day Marijuana Business Conference & Expo (MJBizCon) was held in Las Vegas in mid-November, with an attendance of over 18,000 people. Lexaria Bioscience Corp. (CSE: LXX) (OTCQB: LXRP) had a full team at its exhibit, which attracted a lot of attention. The company noticed increased awareness and knowledge among conference-goers about cannabinoids and their potential health benefits. There was also a noticeable demand for improved edible products in the market, with dispensary owners showing a refreshingly new willingness to carry CBD-based edibles on their shelves and manufacturers displaying a keen interest in Lexaria’s patented DehydraTECH™ delivery technology to incorporate in their products. To accommodate all of the interest shown, as well as requests for business discussions, the company intends to expand its sales team and infrastructure.

Lexaria’s proprietary technology has been awarded patents in the U.S. and Australia, and it has patents pending in more than 40 other countries. Furthermore, it is the only company in the world to date that has a patent allowed for the oral delivery of all non-psychoactive cannabinoids, including CBD, as well as for the delivery of THC and other psychoactive cannabinoids. This delivery technology masks the taste of edibles, eliminating the need for unhealthy sugars and sweeteners used in many products to mask bitter flavors. It also increases bio-absorption of cannabinoids and other active compounds by up to 10 times and reduces the time of onset of effects, which were previously typically 60 to 120 minutes, to between 15 and 20 minutes. These capabilities are in marked contrast to other technologies through which active compounds are bad tasting upon oral intake, broken down by the liver, largely destroyed by stomach acid and unable to cross the intestinal wall to any significant degree.

In August 2015, Lexaria initiated an in vitro study which showed an increase of up to 499 percent in CBD bioabsorption in human intestinal tissues using its technology. In February 2017, Lexaria signed a collaboration agreement with Canada’s National Research Council to investigate the bioavailability enhancement of lipophilic active ingredients and to determine the best methods for processing these active compounds within foods. The company’s patents include a wide range of lipophilic active compounds that can be formulated and delivered using the company’s technology, including cannabinoids, vitamins, NSAIDs and nicotine. They also cover numerous product dosage forms, including foods, liquids, emulsions, tablets and capsules.

Lexaria prides itself on being a technology disruptor in the rapidly emerging cannabis market. For manufacturers, it reduces the cannabinoid per serving unit cost, or it can deliver stronger effects in environments where serving levels are regulated. Consumers benefit greatly from the better taste of edibles and the reduced time to effect. Lexaria has developed several CBD-based products for demonstration, testing and sales, including protein energy bars, CBD tablets, exotic teas and TurboCBD™ high absorption hemp oil capsules. To date, the company has signed royalty agreements with several companies in the United States and Canada.

Overall, Lexaria’s technology enables the lowest cost per serving and best consumer experience, which are major benefits for manufacturers of edibles in an increasingly competitive market. Judging by the level of interest in Lexaria’s patented technology generated at MJBizCon, the company is headed for a very bright future.

For more information, visit the company’s website at www.LexariaBioscience.com

Let us hear your thoughts: Lexaria Bioscience Corp. Message Board

• Carl’s innovative IIoT Big Data platform technology services any industry vertical
• Rapidly expanding Big Data and IIoT market estimated at $14.4 trillion by 2022
• 2016 revenue at $1.08 million with 2018 revenue projection at $3.9 million

Carl Data Solutions Inc. (CSE: CRL) (FSE: 7C5) (OTC: CDTAF), a developer of Big-Data-as-a-Service (“BDaaS”)-based solutions for data integration, business intelligence and Industrial Internet-of-Things (“IIoT”) applications, is headquartered in Vancouver, British Columbia, Canada. The company’s BDaaS enterprise applications platform provides custom cloud-based collection, storage, monitoring and advanced analysis of any data source of any size or complexity.

Carl Data Solutions provides smart, real-time solutions for industries that routinely face an overload of data. The company’s team of dedicated data scientists and application developers build environmental monitoring and modeling technology that collects, connects and manages data to protect industrial and infrastructure assets. As experts in data collection, storage, analytics and reporting, the team is experienced in the complex issues facing governmental and industrial sectors and is well positioned in key IIoT market segments to offer customized solutions.

Among the benefits of CARL’s Big Data solutions: turning vast quantities of information into meaningful, actionable insights for any business; gathering data from multiple sources and monitoring in real-time, allowing for better decision making and forecasting; identifying business performance issues or operational efficiencies quickly and accurately for cost and time savings; and, mitigating risks with predictive analytic capabilities to manage unplanned events.

The company’s most recent acquisitions include:

• FlowWorks, a SaaS-based monitoring, data collection, alarming, modeling and reporting system utilized by major clients across North America.
• abEmbedded Systems Ltd., a Mesh and LoRa advanced telemetry platform using industrial grade custom sensors and data loggers operating in over 250 pump stations across North America.
• Extend to Social (ETS), a social media application that adds a deep analytics layer that provides clients with valuable insights for new marketing campaigns plus behavioral characteristics for customer service, operations and product development.

Carl Data Solutions provides scalable solutions that integrate public data, Smart IIoT and legacy devices that provides real-time alarming and data analysis. Development of a framework that manages large volumes of diverse types of both structured and unstructured data, stored in an unlimited cloud-based platform that offers advanced analytics features for deeper data insights, provides instant analysis of any inbound data. CARL’s applications locate relationships and patterns, which can then predict the probability of specific events, providing valuable insights applicable to any entity dealing with operational issues and regulatory requirements. Both technical and business users are able to quickly and easily understand the impact of environmental events on infrastructure through a comprehensive suite of dashboards, geographic information systems and graphic tools.

The company’s predictive analytics, machine learning, and web-based applications can be utilized for waste and storm water management, in the protection of oil and gas pipeline stream crossings, and by hydro-electric dams and toxic tailing ponds, among other industrial uses. The global industrial IoT market alone is expected to reach USD $933.62 billion by 2025, according to a new report by Grand View Research, Inc. (http://dtn.fm/m8ILh). Businesses are seeking new operating models that will increase overall productivity, enhance operational efficiency, improve visibility and reduce complexities of various processes – all of which are targets of Carl’s Data Solutions.

An expert management team is at the company core with Greg Johnston leading as its president, CEO and director. Johnston is an experienced technology professional with a proven track record of leadership success within both large multinational corporations and small start-up technology ventures.

For more information, visit the company’s website at www.CarlSolutions.com

Let us hear your thoughts: Carl Data Solutions Inc. Message Board